Forward Therapeutics Announces Positive Phase 1 Data for Potential Best-in-Class Oral TNFR1 Signaling Inhibitor FT2109, Supporting Advancement into Phase 2 Development

Phase 1positiveFT2109Positive

AI Analysis

Summary

Forward Therapeutics announced positive Phase 1 data for FT2109, an oral selective TNFR1 signaling inhibitor for inflammation-driven diseases, supporting advancement to Phase 2. Data will be presented at ACR Convergence 2026 in November.

Clinical Trial Data

Phase

Phase 1

Primary Endpoint

Met

Outcome Details

Positive Phase 1 clinical and preclinical data for FT2109, supporting advancement into Phase 2 development

Importance:6/10

Sentiment:

0.75

Phase 1 dataoral small moleculeTNFR1 inhibitorinflammationconference presentation

Related Companies

$INTI $AHR

Read the original article

Published by GlobeNewswire Pharma on October 5, 2026 12:00 PM

Read Original